Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Molecular Insight expands portfolio

January 29, 2007 | A version of this story appeared in Volume 85, Issue 5

Molecular Insight Pharmaceuticals has licensed Onalta, a radiolabeled peptide for the treatment of pancreatic neuroendocrine and carcinoid tumors, from Novartis. Onalta, which has orphan drug status from FDA, has been studied in Phase I and II clinical trials. Earlier this month, Molecular Insight added another radiotherapeutic to its portfolio by licensing Solazed, Bayer Schering Pharma's small molecule labeled with iodine-131 for the treatment of malignant melanoma. Financial terms of the deals were not disclosed, but both include upfront, milestone, and royalty payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.